CANCER:

Thyroid Gland Hurthle Cell Carcinoma

Related cancers:

‹

Thyroid Gland Carcinoma (322)

Thyroid Gland Anaplastic Carcinoma (57)

Thyroid Gland Medullary Carcinoma (55)

Thyroid Gland Papillary Carcinoma (49)

Thyroid Gland Follicular Carcinoma (24)

Thyroid Gland Carcinoma (322)

Thyroid Gland Anaplastic Carcinoma (57)

Thyroid Gland Medullary Carcinoma (55)

Thyroid Gland Papillary Carcinoma (49)

Thyroid Gland Follicular Carcinoma (24)

›

No biomarker No biomarker	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval
NTRK1 fusion NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	denosumab Sensitive: A2 - Guideline
RET fusion RET fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	selpercatinib Sensitive: A2 - Guideline
RET fusion RET fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	pralsetinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline